News

May 18, 2020May 18, 2020

Adcetris Plus Chemo Now First-line Treatment of Adults with sALCL in Europe

News

The European Commission (EC) has approved Adcetris (brentuximab vedotin) when used alongside chemotherapy as a first treatment for adults with systemic anaplastic large cell lymphoma (sALCL), a type of peripheral T-cell ... Read more

May 11, 2020May 11, 2020

FDA Decision on Liso-cel, CAR T-cell Therapy for Large B-cell Lymphoma, Due in November

News

The U.S. Food and Drug Administration (FDA) has extended by three months its review of Bristol-Myers Squibb’s investigational CAR T-cell therapy, lisocabtagene maraleucel (liso-cel), as a treatment for adults with relapsed or refractory large B-cell lymphoma after at ... Read more

May 4, 2020May 4, 2020

Cirmtuzumab-Imbruvica Yields ‘Encouraging’ Response Rates Against Mantle Cell Lymphoma, Ongoing Trial Shows

News

Combination therapy with the investigational treatment cirmtuzumab plus Imbruvica (ibrutinib) led to “highly encouraging” response rates among patients with mantle cell lymphoma (MCL), a type of B-cell cancer, according to the ... Read more

April 27, 2020April 27, 2020

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

News, syndicated

While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their ... Read more

April 20, 2020April 20, 2020

1st Patient Treated in Phase 1 Trial of ATG-019 for Lymphoma, Solid Tumors

News

The first patient has been dosed in Antengene‘s Phase 1 clinical trial investigating the dual inhibitor ATG-019, alone or in combination with niacin extended release, for people with non-Hodgkin’s lymphoma or ... Read more

April 13, 2020April 13, 2020

Keytruda Prolongs Life Without Disease Worsening in Classical Hodgkin’s Lymphoma, Interim Data Confirm

News

Keytruda (pembrolizumab) significantly extends survival without disease worsening in adults with relapsed or refractory classical Hodgkin’s Lymphoma (cHL), compared to treatment with Adcetris (brentuximab vedotin), interim data from a Phase ... Read more

April 6, 2020April 6, 2020

ME-401 Put on FDA’s Fast Track for Previously Treated Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to MEI Pharma‘s investigational compound ME-401 for treating follicular lymphoma patients who received at least two prior therapies. A ... Read more

March 30, 2020March 30, 2020

Zevalin Improves Survival of Non-Hodgkin’s Lymphoma Patients in Real-world Setting, Study Finds

News

Treatment with Zevalin (ibritumomab tiuxetan), which combines an antibody with a radioactive agent, was found to be safe, reduced tumor burden in most patients, and significantly improved survival without disease worsening ... Read more

March 19, 2020March 19, 2020

FDA Grants Orphan Drug Status to Umbralisib for Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TG Therapeutics‘ investigational oral therapy umbralisib for the treatment of follicular lymphoma (FL). The status, which follows another ... Read more

March 17, 2020March 17, 2020

First Patient Treated in MB-106 CAR T-cell Trial Now Cancer Free, Mustang Says

News

The first patient treated in Mustang Bio‘s Phase 1/2 clinical trial testing its investigational MB-106 therapy for B-cell non-Hodgkin’s lymphoma has achieved a complete response to treatment — meaning that all signs of the ... Read more